Table 13.
Primary and Secondary Outcomes Among Participants in the ARISTOTLE, RELY, and ROCKET AF Trials Stratified by Sex
| ARISTOTLE | RELY | ROCKET AF | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | No. of Events (%/y) | n | No. of Events (%/y) | n | No. of Events (%/y) | |||||
| Apixaban | Warfarin | Dabigatran 110 mg | Dabigatran 150 mg | Warfarin | Rivaroxaban | Warfarin | ||||
| Primary outcome | ||||||||||
| Men | 11785 | 132 (1.2) | 160 (1.5) | 11514 | 52(1.35) | 42(1.10) | 57 (1.49) | 8553 | 103 (1.52) | 136 (1.95) |
| Women | 6416 | 80 (1.4) | 105 (1.8) | 6598 | 40(1.86) | 25(1.14) | 45 (2.03) | 5590 | 86 (1.97) | 107(2.47) |
| Major bleeding | ||||||||||
| Men | 11747 | 225 (2.3) | 294 (3.0) | 11514 | 113(2.92) | 129(3.37) | 138(3.63) | 8591 | 260 (3.92) | 253 (3.68) |
| Women | 6393 | 102 (1.9) | 168(3.3) | 6598 | 60 (2.79) | 72 (3.23) | 77 (3.46) | 5645 | 135(3.11) | 133(3.10) |
ARISTOTLE indicates Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation; RELY, Randomized Evaluation of Long-term Anticoagulant Therapy; and ROCKET AF, Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation.